

# SVM All Europe SRI Fund

The objective of the Fund is to achieve capital growth over the long term (5 years or more) and it aims to outperform the MSCI Europe Index. It adopts a positive engagement approach toward investment and enters into meaningful dialogue with companies regarding environmental, social and corporate governance issues. The Fund will invest at least 80% in equities and equity related instruments which are dealt in or traded on all European Eligible Securities Markets. The Fund may invest in other permitted securities.



November 2022 | Share Class B

Factsheet as at 31 October 2022



## Monthly Fund Commentary

The lettuce lasted longer than the Prime Minister. Changes at the top of UK government heralded the reintroduction of a more conventional economic policy and stabilisation in financial markets. The improvement in sentiment was aided by signs that inflationary pressures are continuing to ease. Both equities and gilts rose, albeit small-cap stocks continued to lag. The fund rose 1.7% versus the MSCI Europe Index that gained 3.9%.

Central bank policy continues to shape markets. Both the Bank of England and the Federal Reserve are expected to increase rates by 75bps and signal more rises to come. The second derivative of rate increases, however, is beginning to slow. Increasing evidence of an economic slowdown alongside less hawkish commentary from the Reserve Bank of Australia and the Bank of Canada encouraged investors to focus on the potential for a 'Fed pivot' and pushed markets higher. From the Fed's perspective, though, the resultant easing in financial conditions is likely to make their job more difficult and thus reduces the prospect of a 'pivot'. Markets are therefore likely to remain volatile until there is clearer evidence that inflationary pressures are under control and the economy is slowing.

Ultimately price and/or time corrects all bear markets, be they cyclical or structural. The former type is generally accompanied by declines of 20-30% and lasts 12-18 months. More structural adjustments involve larger declines with more variable time frames. What differentiates the two, typically, are weaknesses in the financial system that can amplify a cyclical downturn into something more serious. This time the financial sector is well capitalised with both consumer and corporate balance sheets reasonably robust.

Interestingly, even in the financial crisis the market decline lasted just over twelve months. Markets peaked in October 2007 and had just about bottomed in October 2008 with a final low in March 2009. Of course, each cycle is different and what worked last time round may work less well today. Wildcards include the war in Ukraine and the impact the stronger dollar may have in accentuating any underlying weaknesses in the global financial system. The next twelve months will see further downgrades to forecasts and investors will need to see the 'whites of the eyes' of the coming recession. It is important to remember, however, that stock markets lead economies and not the other way around. And with the prospect of an economic recovery in 2024 and European equities cheap, both historically and relatively, the upside could be material.

The current forward PE of the portfolio based on market forecasts is c.9x. Inevitably the earnings number will prove too high but by what magnitude is uncertain. Holdings exposed to the UK and European economies are vulnerable but many of these shares have been hit hard already. A majority of our domestic-exposed holdings have fallen 40-50% already and are discounting quite significant declines in earnings. Many of these are household names which we are confident will exit the recession in a better competitive position than when they entered. Once economies stabilise and CEOs feel more comfortable with their own businesses, we expect M&A activity to pick up.

There were few stock-specific factors driving returns.

Fund and index performance source: FE fundinfo

## Fund Facts

**Launch Date:** 31 October 2006

**Benchmark Index:**  
MSCI Europe Index

**IA Sector:** Europe inc UK

**Type of Shares:** Accumulation  
**XD Date:** 31 December  
**Pay Date:** 30 April

**Fund Size:** £13.9m

### Fund Managers:

**Neil Veitch** (Co Fund Manager)  
Appointed: 31/10/2006  
Years at SVM: 17 Industry Experience: 26

**Hugh Cuthbert** (Co Fund Manager)  
Appointed: 31/10/2006  
Years at SVM: 17 Industry Experience: 28

### Fund Charges (OCF\*):

Share Class A 1.98%  
Share Class B 1.23%

\*Ongoing Charges Figure includes Annual Management Charge and additional expenses.

### Minimum Investment:

	Initial	Subsequent
Share Class A	£1,000	£200
Share Class B	£250,000**	£200

\*\*Discounted to £1,000 for Professional Advisers

### Risk and Reward Profile:



The Synthetic Risk & Reward Indicator ('SRRI') may be a guide to the level of risk of the Fund compared with other funds. The SRRI is calculated based on the historical volatility of the fund over the last 5 years and it may not be a reliable indication of the future risk and reward profile of the fund.

- This Fund has been classed as 6 because it has experienced high volatility historically.
- The SRRI category shown is not guaranteed and may change over time.
- The lowest category (1) does not mean risk free and extreme adverse market circumstances can mean you suffer losses in all cases.

As at 30/06/2022

**Past Performance is not a guide to future performance. All financial instruments involve a degree of risk. The value of your investments and any income from them can go down as well as up and you may not get back the amount originally invested.**

**INDEPENDENT THINKING**

## Portfolio Analysis

### Risk Baskets

To help understand the overall balance of the portfolio, stocks are allocated to one of eight risk groups: defensive, cyclical, stable financial, unstable financial, consumer cyclical, oil & gas, mining and finally technology. Most of these groups are self explanatory but financials deserve some clarity. All financials are inherently unstable but in the main, Lloyd's underwriters and General Insurers take less balance sheet risk, so are relatively more stable than Banks or Life Assurers.

Seeing the portfolio broken down into these categories allows an understanding of how aggressive or defensive the overall portfolio is, and where risk is being taken.

Cyclical	33.2	<div></div>
Unstable Financial	23.2	<div></div>
Defensive	15.8	<div></div>
Consumer Cyclical	12.6	<div></div>
Technology	7.2	<div></div>
Stable Financial	0.0	
Mining	0.0	
Oil & Gas	0.0	
Cash	8.0	<div></div>

#### Cyclical 33.2%

Alpha FMC	6.2
Smurfit Kappa Group	5.4
CRH	5.2
Capgemini	4.6
Forterra	3.7

#### Unstable Financial 23.2%

AXA	6.2
Lloyds Banking Group	5.1
OSB Group	5.0
Prudential	4.0
Legal & General	2.9

#### Defensive 15.8%

Uniphar	5.2
Roche Holdings	3.8
DCC	3.5
Smith & Nephew	2.6
Sedana Medical	0.5

#### Consumer Cyclical 12.6%

Norcos	6.2
Dalata Hotel Group	2.4
Tesco	2.3
Marks & Spencer	1.7

#### Technology 7.2%

LungLife AI	2.0
Creo Medical Group	1.5
SoftwareONE	1.4
Temenos	1.1
ActiveOps	0.6

#### Stable Financial 0.0%

#### Mining 0.0%

#### Oil & Gas 0.0%

## This Month's Featured Stock

### Roche SE

Based in Basel Switzerland Roche is one of the world's largest pharmaceutical companies. Specialising in some of the most pressing clinical specialities for drug development, such as oncology, neuroscience, immunology and ophthalmology, the pharmaceutical division represents roughly 70% of sales. The remaining 30% is represented by the diagnostics segment that manufactures and sells in vitro tests for the diagnosis of diseases such as cancer, diabetes and Covid-19 among many others.

Despite the long-term nature of the investment case there is interesting news flow to come in the short term that is likely to prove significant for the company. In November we should receive the

results of a clinical study for the Alzheimer's drug Gantenerumab which has recently gained support from the success of a treatment for a competitor product. While a poor result will of course be bad news for Roche, success will have positive ramifications for many years to come so the risk reward into this event appears favourable.

Of course, such innovation is costly, and this is reflected in the high price Roche often charges for its medicines. To ensure the products are not available only to rich developed nations Roche has a pricing policy which commits the company to the concept of International Differential Pricing. This helps provide affordable pharmaceuticals for all regardless of GDP per capita. We have recently

approached Roche regarding this policy with the aim of assessing the level of compliance. While it is difficult for a third party to gain a true insight, as stakeholders we can at the very least express our concern over the compliance matter.

## Portfolio Structure

As an unconstrained fund we invest in our highest conviction ideas irrespective of market capitalisation, country or sector. As a consequence The SVM All Europe SRI Fund portfolio will vary considerably from the benchmark index and from other funds that are in the same IA sector.

### Top 10 Holdings

	(%)	
Norcros	6.2	
AXA	6.2	
Alpha FMC	6.2	
Smurfit Kappa Group	5.4	
Uniphar	5.2	
CRH	5.2	
Lloyds Banking Group	5.1	
OSB Group	5.0	
Capgemini	4.6	
Prudential	4.0	
<b>Rest of Portfolio</b>	<b>46.9</b>	

### Country Breakdown

	No. of Stocks	(%)	
UK	18	55.8	
Ireland	4	18.3	
France	2	10.8	
Switzerland	3	6.3	
Sweden	1	0.5	
Germany	1	0.4	
Other	-	0.0	


### Sector Breakdown

	(%)	
Financials	23.2	
Industrials	19.4	
Materials	16.5	
Health Care	15.8	
Information Technology	8.4	
Consumer Discretionary	4.8	
Consumer Staples	4.0	
Energy	0.0	
Communication Services	0.0	
Utilities	0.0	
Real Estate	0.0	



### Size Analysis

	(%)
Mega Cap (>€50bn)	10.0
Large Cap (<€50bn)	24.2
Mid Cap (<€10bn)	29.4
Small Cap (<€1bn)	28.5



### Currency Exposure

	(%)
Euro	29.4
Sterling	55.8
Swiss Franc	6.3
Swedish Krona	0.5

## Enquiries

[www.svmonline.co.uk](http://www.svmonline.co.uk)  
Calls may be recorded

### Investor Services and Dealing:

Dealing, account enquiries and valuations  
Phone: 0345 066 1110  
Fax: 0330 123 3755  
International phone: +44 (0)1268 447 417  
International fax: +44 (0)1268 457 731

### General Enquiries

Head office and fund enquiries  
Phone: +44 (0)131 226 6699  
Email: [info@svmonline.co.uk](mailto:info@svmonline.co.uk)  
Fund Information: 0800 0199 110  
Literature Request: 0800 0199 110

### ISIN:

Share Class A GB00B1FL7S17  
Share Class B GB00B1FL7V46

### MEX:

Share Class A SXSRIA  
Share Class B SXSRI B

### SEDOL:

Sedol GBP B1FL7S1  
Sedol GBP B1FL7V4

### Registered Office:

SVM Asset Management Limited  
7 Castle Street  
Edinburgh  
EH2 3AH  
Registered No. 125817

Issued by SVM Asset Management Limited who is authorised and regulated by the Financial Conduct Authority:  
12 Endeavour Square  
London E20 1JN

© SVM Asset Management Limited.

## Fund Performance

to 31/10/2022

### Cumulative Performance, % change

	One month	2022 yr to date	One year	Three years	Five years	Since launch*
SVM All Europe SRI Fund B	1.7	-25.9	-24.7	5.9	-0.6	225.9
MSCI Europe Index	3.9	-9.8	-7.6	12.7	19.1	149.6
IA Europe inc UK Sector**	3.8	-13.7	-11.9	12.9	16.9	146.5

Source: FE fundinfo, as at 31/10/2022, B Share Class, GBP, UK net tax with net income reinvested and no initial charges.

\*The Fund was launched on 31 October 2006


\*\*IA is provided as a comparator

### Percentage growth year on year to 30 September

	2022	2021	2020	2019	2018
SVM All Europe SRI Fund B	-25.2	41.3	-2.8	-4.0	2.4
MSCI Europe Index	-8.6	22.7	-4.9	5.7	3.2
Performance Difference	-16.6	+18.6	+2.1	-9.7	-0.8

Source: FE fundinfo, as at 30/09/2022, B Share Class, GBP, UK net tax with net income reinvested and no initial charges.

### Five Year Performance (%)



Source: FE fundinfo, as at 31/10/2022, B Share Class, GBP, UK net tax with net income reinvested and no initial charges.

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct but it neither warrants, represents nor guarantees the contents of the information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein.

### Past performance is not a guide to future performance.

**The value of your investments and any income from them can go down as well as up and you may not get back the amount originally invested.**

**This material should not be considered as advice or an investment recommendation. Investors should seek advice from an authorised financial adviser prior to making investment decisions.**

The Fund is to be considered a long term (5 years or more) investment option.

### The Fund incurs the following key risks:

In the event a preliminary charge is levied and an Investor then redeems the investment shortly after investing, they may not get back the original amount due to the initial charges; regardless of any market movements. Tax treatment can change at any time without notice and is beyond control of the Fund. Expenses incurred by the Fund that are chargeable can reduce income and restrain the capital growth of the Fund. Currency movements may cause the value of your investment to fall as well as rise. Stock market volatility may impact the Fund's ability to trade in, or obtain accurate valuations for, securities held in the Fund's portfolio. There can be no guarantee that the investment objective of a Fund will be achieved or provide the returns sought by the Fund. The Fund may enter into derivative contracts for efficient portfolio management (EPM) purposes. Full details on EPM can be found in Appendix A of the Prospectus. Further information about the risk factors relevant to the Fund can be found in the Prospectus and the Key Investor Information Document.

Unless otherwise stated all data is sourced to SVM.

Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.